A new study reveals that the prognostic test for ER+-HER2 breast cancer can predict the recurrence of the disease in premenopausal women. The study, published in the Journal of the American Association for Cancer Research, represents the first clinical validation of endopredict testing in a premenopausal population.
In the study, tumor samples from 385 premenopausal women with primary ER+-HER2 breast cancer who did not undergo chemotherapy treatments were examined. The results showed that the endopredict test accurately identified that premenopausal women with and without lymph nodes could avoid chemotherapy treatments because the chance of recurrence of the disease is low.
More in-
Dr. Ralph Cronenvat, director of international medical relations at Myriad Genetics said: “In light of the growing clinical recommendations to reduce breast cancer overtreatment, the results are particularly encouraging. When about a third of all new breast cancer cases occur in patients aged 54 and under, the use of endopredict testing among premenopausal women provides important insights to provide information for tailored treatment, including whether or not there is an advantage in using chemotherapy.”
More in-
Endopredict testing is a prognostic test that predicts a patient’s risk of breast cancer recurrence in order to help identify who can safely consider forgoing chemotherapy. It analyzes 12 genes to create a molecular score that is combined with tumor characteristics such as its size and lymph node status to determine patient risk levels.